Consumers can easily re-prompt a chatbot, but enterprises cannot afford mistakes like shutting down the wrong server. This high-stakes environment means AI agents won't be given autonomy for critical tasks until they can guarantee near-perfect precision and accuracy, creating a major barrier to adoption.

When an AI agent errs in a medical or financial context, it is legally unclear who is liable: the AI lab, the deploying company, or the end-user. This novel legal problem, which challenges a century of precedent, creates significant friction and will slow agent adoption in regulated industries.

While media focuses on "rogue AI," the more immediate danger is that organizations will be too fearful to deploy agents due to a lack of governance. This distrust prevents them from realizing significant productivity gains, making the opportunity cost the biggest risk of all.

Despite AI models showing dramatic improvements, enterprise adoption is slow. The key barriers are not capability gaps but concerns around reliability, safety, compliance, and the inability to predictably measure and upgrade performance in a corporate environment. This is an operational challenge, not a technical one.

In regulated industries like finance, the primary barrier to full AI automation is often regulation, not just user trust. It is the technology provider's responsibility to prove AI's reliability and safety to regulators, much like the industry did to legitimize e-signatures over a decade ago.

Large enterprises will likely implement strict guardrails on AI agents due to governance and security fears, slowing adoption. In contrast, small to mid-sized businesses with higher risk tolerance will experiment more freely, potentially achieving disproportionate benefits despite facing greater risks.

Regulators like the FDA are actively encouraging the use of AI to improve clinical trial success rates. However, pharmaceutical companies are hesitant to adopt these innovative methods, fearing that any deviation from traditional processes will lead to costly delays or orders to restart the trial.

Unlike frontier model companies, traditional enterprises in sectors like retail or finance are more receptive to governance and cautious AI rollouts. Since AI is a tool and not their core identity, they can objectively assess its risks without challenging their fundamental business model.

Society holds AI in healthcare to a much higher standard than human practitioners, similar to the scrutiny faced by driverless cars. We demand AI be 10x better, not just marginally better, which slows adoption. This means AI will first roll out in controlled use cases or as a human-assisting tool, not for full autonomy.